The Medicinal 91AV Divisions of the two Belgian Chemical Societies, Société Royale de Chimie (SRC) and Koninklijke Vlaamse Chemische Vereniging (KVCV), are organising every year an international one-day symposium with the aim to update participants on selected areas of pharmaceutical research by specialists in their respective field.
The programme of the day will include six invited lectures and three oral communications selected from submitted abstracts.
This year, the symposium will delve around the latest developments in medicinal chemistry in the field of kinase inhibitors. With more than 35 small molecules approved by the FDA, mainly in oncology, kinase inhibition is still the subject of intense research efforts in both academia and industry. Several recent case studies in various therapeutic areas (transplant rejection, inflammation, oncology) will be presented by industrial speakers. Current challenges such as covalent inhibition, the importance of residence time, or the crucial issue of selectivity will also be addressed through presentations focusing on aspects of molecular biology or chemoinformatics.
In recent years, this symposium has been gathering around 150 participants at each edition, half from universities, half from industry, both from Belgium and surrounding countries. It has been focussing on topics such as:
The programme of the day will include six invited lectures and three oral communications selected from submitted abstracts.
This year, the symposium will delve around the latest developments in medicinal chemistry in the field of kinase inhibitors. With more than 35 small molecules approved by the FDA, mainly in oncology, kinase inhibition is still the subject of intense research efforts in both academia and industry. Several recent case studies in various therapeutic areas (transplant rejection, inflammation, oncology) will be presented by industrial speakers. Current challenges such as covalent inhibition, the importance of residence time, or the crucial issue of selectivity will also be addressed through presentations focusing on aspects of molecular biology or chemoinformatics.
In recent years, this symposium has been gathering around 150 participants at each edition, half from universities, half from industry, both from Belgium and surrounding countries. It has been focussing on topics such as:
- The Many Pharmacotherapeutic Faces of Nucleosides and Oligonucleotides (2017)
- PET & Imaging : From 91AV Lab to Clinical Applications (2016)
- New Vistas in GPCR Research: the Dawn of an Exciting Drug Discovery Era? (2014)
- Constrained Peptides and Macrocycles – New Opportunities for Drug Discovery (2013)
- From Rapid Dissociation to Irreversible Inhibition – Optimisation of Drug-Target Residence Time (2012)
